Frequency of Administration of Erythropoiesis‐Stimulating Agents for the Anaemia of End‐Stage Kidney Disease in Dialysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1440-1797|20|9|663-665

ISSN： 1320-5358

Source： NEPHROLOGY, Vol.20, Iss.9, 2015-09, pp. : 663-665

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of renal anaemia with erythropoiesis‐stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis

By  

NEPHROLOGY, Vol. 20, Iss. S4, 2015-12 ,pp. : 29-32

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of Anaemia with Erythropoiesis-Stimulating Agents in Patients with Chronic Kidney Disease Does Not Lower Mortality and May Increase Cardiovascular Risk: A Meta-Analysis

By  

Nephron Clin Pract, Vol. 121, Iss. 3-4, 2012-11 ,pp. : c95-c101

Karger

Access to resources Recommend Favorite

Cochrane commentary

By  

NEPHROLOGY, Vol. 20, Iss. 4, 2015-04 ,pp. : 302-303

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation and Determinants of Underprescription of Erythropoiesis Stimulating Agents in Pre-Dialysis Patients with Anaemia

By  

Nephron Clin Pract, Vol. 108, Iss. 1, 2008-01 ,pp. : c67-c74

Karger

Access to resources Recommend Favorite

Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents*

By Silver M. R.   Geronemus R.   Krause M.   Chen C. Y.   Kewalramani R.   Stehman-Breen C.  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 123-131

Informa Healthcare

Access to resources Recommend Favorite